Baudax Bio Inc (BXRXQ)
OTCMKTS: BXRXQ · Delayed Price · USD
0.00
0.00 (0.00%)
No quote available

Company Description

Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care related settings.

The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with other non-NSAID analgesics.

It also develops BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMB, which is in phase I clinical trial, as well as a proprietary blockade reversal agent; and BX3000, a NMB reversal agent that is in preclinical studies.

Baudax Bio, Inc. was incorporated in 2019 and is based in Malvern, Pennsylvania. On February 22, 2024, Baudax Bio, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Eastern District of Pennsylvania.

Baudax Bio Inc
Baudax Bio logo
Country Panama
Industry Biotechnology
Sector Healthcare
Employees 9

Contact Details

Address:
490 Lapp Road
Malvern, Pennsylvania 19355
United States
Phone 484-395-2470

Stock Details

Ticker Symbol BXRXQ
Exchange OTCMKTS
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001780097
Employer ID 47-4639500
SIC Code 2834

Key Executives

Name Position
Dr. Geraldine A. Henwood Ph.D. President, Chief Executive Officer and Director
Mike Choi Vice President of Financial Planning and Analysis
Natalie McAndrew Consultant and Principle Accounting Officer
Dr. Chan Kim Yong Ph.D. Chief Scientific Officer and Director

Latest SEC Filings

Date Type Title
Feb 28, 2024 8-K Current Report
Feb 15, 2024 25-NSE Filing
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 6, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Dec 13, 2023 8-K Current Report
Nov 22, 2023 424B3 Prospectus
Nov 20, 2023 10-Q Quarterly Report
Nov 15, 2023 NT 10-Q Notification of inability to timely file Form 10-Q or 10-QSB
Nov 15, 2023 8-K Current Report
Oct 25, 2023 8-K Current Report